netFormulary
 Report : Medicines with links to NICE 04/07/2020 03:35:37

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abemaciclib 08.01.05 Restricted Use NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Restricted Use NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 250mg 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 250mg 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Aclidinium/ formoterol inhaler 03.01.04 Formulary NICE CG101: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Adalimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 01.05.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 01.05.03 Restricted Use NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 40mg 13.05.03 Restricted Use NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 40mg 13.05.03 Restricted Use NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 40mg 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 40mg 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adalimumab 40mg 11.04.02 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 40mg 13.05.03 Restricted Use NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 40mg 13.05.03 Restricted Use NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 40mg 11.04.02 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 10mg 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA96
Afatinib 08.01.05 Restricted Use NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 08.01.05 Non Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 40mg/1mL 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 40mg/1mL 11.08.02 Formulary NICE TA294: Macular degeneration (wet age-related) - aflibercept
Aflibercept 40mg/1mL 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 40mg/1mL 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Alectinib 150mg 08.01.05 Restricted Use NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Restricted Use NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab 75mg/mL, 150mg/mL 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 10mg, 20mg & 50mg 02.10.02 Restricted Use NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Alteplase 10mg, 20mg & 50mg 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Restricted Use NICE TA156: Anti-D in pregnant women
Apixaban 2.5mg & 5mg 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 2.5mg & 5mg 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apremilast 13.05.03 Restricted Use NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 10.01.03 Restricted Use NICE TA 433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Restricted Use NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Restricted Use NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Restricted Use NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 1200mg 08.01.05 Restricted Use NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 1200mg 08.01.05 Restricted Use NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 1200mg 08.01.05 Restricted Use NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 1200mg 08.01.05 Restricted Use NICE TA 638 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 1200mg 08.01.05 Restricted Use NICE TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 1200mg 08.01.05 Restricted Use TA 639 Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Avatrombopag 09.01.04 Restricted Use NICE TA 626 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab 20mg/mL 08.01.05 Restricted Use NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel 08.01.05 Restricted Use NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Restricted Use NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Restricted Use NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 2mg, 4mg 10.01.03 Restricted Use NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Belimumab 10.01.05 Restricted Use NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Restricted Use NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Restricted Use NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Binimetinib 15mg 08.01.05 Restricted Use NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Bivalirudin 250mg 02.08.01 Restricted Use NICE CG94: Unstable angina and NSTEMI
Bivalirudin 250mg 02.08.01 Restricted Use NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Restricted Use NICE TA450:Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.02 Restricted Use NICE TA 589 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Formulary NICE TA299: Leukaemia (chronic myeloid) - bosutinib
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Bosutinib 08.01.05 Restricted Use NICE TA401: Bosutinib for previously treated CML.
Botulinum Toxin Type A 04.09.03 Formulary NICE TA 605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Botulinum Toxin Type A 04.07.04.02 Restricted Use NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 50mg 08.01.05 Restricted Use NICE TA 577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 50mg 08.01.05 Restricted Use NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 50mg 08.01.05 Restricted Use NICE TA8524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuxumab 08.01.05 Restricted Use NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brigatinib 08.01.05 Restricted Use NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 210mg 13.05.03 Restricted Use NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Buprenorphine 200microgram, 400microgram 04.07.02 Formulary NICE TA114: Methadone and buprenorphine for the management of opioid dependence
Buprenorphine 35, 52.5, 70 microgram 04.07.02 Formulary NICE TA114: Methadone and buprenorphine for the management of opioid dependence
Cabazitaxel 08.01.05 Restricted Use NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Restricted Use NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA516: Cabozantinib for treating medullary thyroid cancer
Canagliflozin 06.01.02.03 Restricted Use NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cannabidiol 04.08.01 Restricted Use NICE TA 615 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol 04.08.01 Restricted Use NICE TA 614 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Capecitabine 08.01.03 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Restricted Use NICE TA61: Metastatic colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Restricted Use NICE TA191: Gastric cancer (advanced) - capecitabine
Carfilzomib 10mg. 30mg, 60mg 08.01.05 Restricted Use NICE TA457:Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cemiplimab 08.01.05 Restricted Use NICE TA 592 Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 08.01.05 Restricted Use NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Restricted Use NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 200 mg Injection 13.05.03 Restricted Use NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 200mg 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 200mg 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 200mg 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cetuximab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Ciclosporin 1mg/mL 11.08.01 Restricted Use NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Restricted Use NICE TA 616 Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 75mg 02.09 Formulary NICE TA80: Acute coronary syndromes - clopidogrel
Clopidogrel 75mg 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate inhaler 05.01.07 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Restricted Use NICE TA459:Collagenase clostridium histolyticum for Dupuytren’s contracture
Crizotinib 08.01.05 Restricted Use NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase- positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cubitan A2.03.02 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cytarabine - Daunorubicin (liposomal) 08.01.02 Restricted Use NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran 75mg & 110mg 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran 75mg & 110mg 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 75mg & 110mg 02.08.02 Formulary NICE TA157: VTE prevention post hip / knee surgery - dabigatran
Dabrafenib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Formulary NICETA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 60mg 05.03.03.02 Non Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 150mg 08.02.02 Non Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib 08.01.05 Restricted Use TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Restricted Use TA597 Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Restricted Use NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Daratumumab 20mg/mL 08.01.05 Restricted Use NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Daratumumab 20mg/mL 08.01.05 Restricted Use NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Dasabuvir 250mg 05.03.03.02 Restricted Use NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 80mg, 120mg 08.03.04.02 Restricted Use NICE TA 404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 120mg 06.06.02 Restricted Use NICE TA265: Bone metastases from solid tumours - denosumab
Denosumab 60mg/1mL 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone 700micrograms 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dexamethasone 700micrograms 11.04.01 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone 700micrograms 11.04.01 Restricted Use NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 120mg & 240mg 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumarate 30mg, 120mg 08.02.04 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinutuximab 08.02.03 Restricted Use NICE TA538: Dinutuximab beta for treating neuroblastoma
Disulfiram 04.10.01 Restricted Use NICE CG115: Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
Docetaxel 08.01.05 Restricted Use NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Restricted Use NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Dronedarone 02.03.02 Restricted Use NICE TA197: Atrial fibrillation - dronedarone
Dupilumab 13.05.01 Restricted Use NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Restricted Use NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
edoxaban 02.08.02 Non Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
edoxaban 02.08.02 Non Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 30mg & 60mg 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 30mg & 60mg 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir & grazoprevir 50mg/ 100mg 05.03.03.02 Restricted Use NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 25mg, 50mg 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Eluxadoline 75mg, 100mg 01.06.06 Restricted Use NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Restricted Use NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Encorafenib 50mg, 75mg 08.01.05 Restricted Use NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 500microgram, 1mg 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 500microgram, 1mg 05.03.03.01 Restricted Use NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 40mg 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 40mg 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Eribulin 08.01.05 Restricted Use NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer
Eribulin 08.01.05 Restricted Use NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.05 Non Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Non Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Erlotinib 08.01.05 Non Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Non Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Erlotinib 08.01.05 Restricted Use NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 15mg 06.01.02.03 Restricted Use NICE TA572 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 15mg 06.01.02.03 Restricted Use NICE TA583 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Erythromycin 05.01.05 Formulary NICE Evidence Summary: Gastroparesis in adults: oral erythromycin
Etanercept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 13.05.03 Restricted Use NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Restricted Use NICE TA103: Psoriasis - efalizumab and etanercept
Etelcalcetide 2.5mg, 5mg, 10mg 09.05.01.02 Restricted Use NICE TA448:Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.02.02 Non Formulary NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.01.05 Restricted Use NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Restricted Use NICE TA421: Everolimus with Exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Restricted Use NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 140mg/mL 02.12 Restricted Use NICE TA 394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Restricted Use NICE TA248: MR exenatide
Ezetimibe 10mg 02.12 Restricted Use NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Ezetimibe 10mg 02.12 Restricted Use NICE CG71: Familial hypercholesterolaemia: identification and management
Febuxostat 80mg , 120mg 10.01.04 Restricted Use NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout
Finasteride 5mg 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 500microgram 08.02.04 Restricted Use NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Restricted Use NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Restricted Use NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone 190microgram 11.04.01 Restricted Use NICE TA613 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
Fluocinolone 190microgram 11.04.01 Restricted Use NICE TA 590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uvetitis
Fluocinolone 190microgram 11.04.01 Restricted Use NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Fluoxetine 04.03.03 Formulary NICE CG28: Depression in children and young people: identification and management
Fremanezumab 04.07.04.02 Restricted Use NICE TA 613 Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Non Formulary NICE TA503: Fulvestrant for untreated locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Restricted Use NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Restricted Use NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Restricted Use NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Gemtuzumab 08.02.03 Restricted Use NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 20mg/1mL & 40mg/1mL 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir & Pibrentasvir 100mg/ 40mg 05.03.03.02 Restricted Use NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Glycopyrrolate/ indacaterol inhaler 03.01.04 Formulary NICE CG101: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Golimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Golimumab 50mg, 100mg 10.01.03 Restricted Use NICE TA220: Psoriatic arthritis - golimumab
Golimumab 50mg, 100mg 10.01.03 Restricted Use NICE TA233: Ankylosing spondylitis - golimumab
Golimumab 50mg, 100mg 10.01.03 Restricted Use NICE TA225: Rheumatoid arthritis - golimumab
Golimumab 50mg, 100mg 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Guselkumab 13.05.02 Restricted Use NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Hydrogen Peroxide 13.11.06 Formulary Impetigo: antimicrobial prescribing
Ibrutinib 140mg 08.01.05 Restricted Use NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 140mg 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 140mg 08.01.05 Restricted Use NICE TA429: Ibrutinib for previously treated CLL
Idelalisib 08.01.05 Restricted Use NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinob and imatinib for untreated CML
Imatinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating resistant CML
Imatinib 08.01.05 Restricted Use NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Restricted Use NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Restricted Use NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Restricted Use NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Indapamide 02.02.01 Formulary Hypertension in adults: diagnosis and management
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Restricted Use NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 100mg 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 100mg 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 100mg 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 100mg 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Inotuzumab 08.02.03 Restricted Use NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Insulin 06.01.01.01 Non Formulary Nice web site
Interferon beta 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Restricted Use NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan Hydrochloride 08.01.05 Restricted Use NICE CG131: Colorectal cancer: diagnosis and management
Ivabradine 5mg & 7.5mg 02.06.03 Restricted Use NICE CG126: Guidance on Stable Angina July 2011
Ivabradine 5mg & 7.5mg 02.06.03 Restricted Use NICE TA267: Chronic heart failure - Ivabradine November 2012
Ixazomib 08.01.05 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 80mg 13.05.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 80mg 13.05.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Labetalol 02.04 Formulary NICE CG107: Hypertension in pregnancy: diagnosis and management
Lanadelumab 03.04.03 Restricted Use NICE TA 606 Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib 08.01.05 Restricted Use NICE TA 630 Larotrectinib for treating NTRK fusion-positive solid tumours
Ledipasvir and Sofosbuvir 400mg/ 90mg 05.03.03.02 Restricted Use NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Restricted Use NICE TA 586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Restricted Use NICE TA 627 Lenalidomide with rituximab for previously treated follicular lymphoma
Lenalidomide 08.02.04 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Lenalidomide 08.02.04 Restricted Use NICE TA 587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Restricted Use NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Restricted Use NICE TA171: Multiple myeloma - lenalidomide
Lenvatinib 08.01.05 Restricted Use NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Restricted Use NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Restricted Use NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Letermovir 05.03 Restricted Use NICE TA 591 Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Liposomal Doxorubicin Hydrochloride 08.01.02 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cance
Liraglutide 06.01.02.03 Restricted Use Type 2 diabetes in adults: management (NG28) (Dec 15)
Lorlatinib 08.01.05 Restricted Use NICE TA 628 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lusutrombopag 09.01.04 Restricted Use NICE TA 617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Mannitol inhalation 03.07 Non Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Mepolizumab 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma Jan2017
Methyldopa 02.05.02 Formulary NICE CG107: Hypertension in pregnancy: diagnosis and management
Methylprednisolone 06.03.02 Restricted Use NICE CG8: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 25mg 08.01.05 Restricted Use NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Non Formulary NICE TA154: Hepatitis B - telbivudine
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl Oxalate 100mg 02.06.04 Restricted Use NICE CG147: Peripheral arterial disease: diagnosis and management
Naftidrofuryl Oxalate 100mg 02.06.04 Restricted Use NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Nalmefene 04.10.01 Restricted Use NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Restricted Use NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Restricted Use NICE TA115: Drug misuse - naltrexone
Naltrexone/ bupropion 04.05.01 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Neratinib 08.01.05 Restricted Use NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated CML
Nilotinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating resistant CML
Nintedanib 08.01.05 Restricted Use NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nintedanib 100mg, 150mg 03.11 Restricted Use NICE TA379: Nintedanib for treating indiopatic pulmonary fibrosis
Niraparib 100mg 08.01.05 Restricted Use NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA462:Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 10mg/1mL 08.02.04 Restricted Use NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nusinersen 12 mg 10.02 Restricted Use NICE TA 588 Nusinersen for treating spinal muscular atrophy
Obinutuzumab 08.02.03 Restricted Use NICE TA 629 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Obinutuzumab 08.02.03 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Restricted Use NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocrelizumab 08.02.02 Restricted Use NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.02 Restricted Use NICE TA585 Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 0.5mg/0.2mL 11.08.02 Restricted Use NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Restricted Use NICE TA202: Chronic lymphocytic leukaemia - ofatumumab
Olaparib 20 Non Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaparib 08.01.05 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer
Olaparib 08.01.05 Formulary NICE TA620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.01.05 Formulary NICE TA598 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaratumab 08.01.05 Non Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 150mg 03.04.02 Restricted Use NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Omalizumab 150mg 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Restricted Use NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Orlistat 04.05.01 Formulary NICE CG43: Obesity prevention
Oxaliplatin 08.01.05 Restricted Use NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Oxybutynin Hydrochloride 07.04.02 Restricted Use NG123: Urinary incontinence and pelvic organ prolapse in women: management
Paclitaxel 08.01.05 Restricted Use NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Restricted Use NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel - Albumin Bound Formulation 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 75mg, 100mg, 125mg 08.01.05 Restricted Use NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Palbociclib 75mg, 100mg, 125mg 08.01.05 Restricted Use NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Restricted Use NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer 09.02.01.01 Formulary NICE TA 623 Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Restricted Use NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa-2a 135mcg, 180mcg 08.02.04 Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon beta-1a 08.02.04 Formulary NICE TA 624 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Restricted Use NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Restricted Use NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Restricted Use NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Restricted Use NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Restricted Use NICE TA522:Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Restricted Use NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA428: Pembrolizumab for treating PD-L1-positive NSC lung cancer
Pemetrexed 08.01.03 Restricted Use NICE TA402: Pemetrexed for non-squamous, non-small cell lung cancer
Pemetrexed 08.01.03 Restricted Use NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Restricted Use NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Restricted Use NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Restricted Use NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Pentosan Polysulphate 07.04.03 Restricted Use NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome
PENTOSAN POLYSULPHATE Capsules 50 mg 20 Formulary NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome
Perampanel 04.08.01 Non Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Restricted Use NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Restricted Use NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 1% 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pioglitazone 06.01.02.03 Restricted Use Type 2 diabetes in adults: management (NG28) (Dec 15)
Pirfenidone 267mg 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Restricted Use NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Pomalidomide 08.02.04 Restricted Use NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 15mg, 30mg, 45mg 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Restricted Use NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
Prasugrel 02.09 Restricted Use NICE TA182: Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Restricted Use NICE TA211: Constipation (women) - prucalopride
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE TA160: quick reference guide on osteoporosis
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raltitrexed 08.01.03 Restricted Use NICE CG131: Colorectal cancer: diagnosis and management
Ramucirumab 08.01.05 Non Formulary NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ramucirumab 08.01.05 Non Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Ranibizumab 0.5mg/0.5mL 11.08.02 Restricted Use NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranibizumab 0.5mg/0.5mL 11.08.02 Restricted Use NICE TA155: Macular degeneration (age-related) ranibizumab
Ranibizumab 0.5mg/0.5mL 11.08.02 Restricted Use NICE TA274: Macular oedema (diabetic) - ranibizumab
Ranibizumab 0.5mg/0.5mL 11.08.02 Restricted Use NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina July 2011
Regorafenib 40mg 08.01.05 Restricted Use NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 40mg 08.01.05 Restricted Use NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 40mg 08.01.05 Restricted Use NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Restricted Use NICE TA479: Reslizumab for treating severe eosinophilic asthma Oct 2017
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 200mg 05.03.05 Restricted Use NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Ribavirin 200mg 05.03.05 Restricted Use NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Ribavirin 200mg 05.03.05 Restricted Use NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribociclib 200mg 08.01.05 Restricted Use TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Ribociclib 200mg 08.01.05 Restricted Use NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 550mg 05.01.07 Restricted Use NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 50mg 04.09.03 Restricted Use NICE TA20: Motor neurone disease - riluzole
Riluzole 5mg/mL 04.09.03 Restricted Use NICE TA20: Motor neurone disease - riluzole
Risankizumab 13.05.03 Restricted Use NICE TA 596 Risankizumab for treating moderate to severe plaque psoriasis
Rituximab 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA243: Follicular lymphoma - rituximab (review)
Rituximab 08.02.03 Formulary NICE TA110: Follicular lymphoma - rituximab Non-Hodgkin's lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab 08.02.03 Formulary NICE TA65: Non-Hodgkin’s lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 500mg/50mL 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab 500mg/50mL 10.01.03 Restricted Use NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 10mg, 15mg & 20mg 02.08.02 Formulary NICE TA256: Rivaroxaban for AF
Rivaroxaban 10mg, 15mg & 20mg 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
Rivaroxaban 10mg, 15mg & 20mg 02.08.02 Formulary NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 10mg, 15mg & 20mg 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 2.5mg 02.08.02 Formulary NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Roflumilast 03.03.03 Restricted Use NICE TA461:Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Rucaparib 08.01.05 Restricted Use NICE TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Restricted Use NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril and valsartan 02.05.05.02 Restricted Use NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 150mg, 200mg 10.01.03 Restricted Use NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 150mg 10.01.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with NSAIDs or TNF-alpha inhibitors
Secukinumab 150mg 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Simeprevir 150mg 05.03.03.02 Restricted Use NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA332: Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
Sodium Tetradecyl Sulphate 02.13 Formulary NICE CG168: Varicose veins: diagnosis and management
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir / velpatasvir 400mg/100mg 05.03.03.02 Restricted Use NICE TA430: Sofosbuvir-velpatasvir for treating chronic hepatitis C
Sofosbuvir 400mg 05.03.03.02 Restricted Use NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir 400mg/ Velpatasvir 100mg/ Voxilaprevir 100mg 05.03.03.02 Restricted Use NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 200mg 08.01.05 Restricted Use NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 200mg 08.01.05 Restricted Use NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Streptokinase 1.5 Mega Unit 02.10.02 Formulary TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Sunitinib 08.01.05 Restricted Use NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Restricted Use NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Restricted Use NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Restricted Use NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 10mg, 20mg 07.04.05 Restricted Use NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Tegafur with Uracil 08.01.03 Restricted Use NICE TA61: Capcitabine and tegafur - Colorectal cancer
Temozolomide 08.01.05 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Restricted Use NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Tenofovir Disproxil 05.03.01 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Restricted Use NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Restricted Use NICE TA303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Restricted Use NICE TA161 : Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Restricted Use NICE TA 228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Thiamine 09.06.02 Formulary NICE CG100: Alcohol-use disorders: diagnosis and management of physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
Ticagrelor 90mg 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after MI
Ticagrelor 90mg 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after MI
Tildrakizumab 13.05.03 Restricted Use NICE TA 575 Tildrakizumab for treating moderate to severe plaque psoriasis
Tiotropium / olodaterol® 03.01.04 Formulary NICE CG101: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Tirofiban 250microgram in 1ml 02.09 Restricted Use NICE TA 47: The use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Tisagenlecleucel 08.01.05 Restricted Use NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel 08.01.05 Restricted Use NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 890mcg, 1340mcg 08.01.05 Restricted Use NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 28mg 05.01.04 Restricted Use NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Restricted Use NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
Tocilizumab 10.01.03 Restricted Use NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01.03 Restricted Use NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 5mg, 10mg 01.05.03 Restricted Use NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 15mg 06.05.02 Restricted Use NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Restricted Use NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Restricted Use NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trametinib 08.01.05 Restricted Use NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trametinib 08.01.05 Restricted Use NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA 632 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Trifluridine-tipiracil 15mg/6.14mg, 20mg/8.19mg 08.01.03 Restricted Use NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 45mg, 90mg 10.01.03 Restricted Use NICE TA340 - treating active psoriatic arthritis
Ustekinumab 45mg, 90mg 13.05.03 Restricted Use NICE TA180: Psoriasis - ustekinumab
Ustekinumab 45mg, 90mg 13.05.03 Restricted Use NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 45mg, 90mg, 130mg 01.05.03 Restricted Use NICE TA 633 Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 45mg, 90mg, 130mg 01.05.03 Restricted Use NICE TA456:Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Varenicline 04.10.02 Restricted Use NICE TA123: Varenicline
Vedolizumab 01.05.03 Restricted Use NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Restricted Use NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Restricted Use NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Vemurafenib 08.01.05 Restricted Use NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Venetoclax 10mg, 50mg, 100mg 08.01.05 Restricted Use NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 10mg, 50mg, 100mg 08.01.05 Restricted Use NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verapamil 02.06.02 Formulary NICE Clinical Knowledge Summary: Headache - cluster
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 150mg 08.01.05 Restricted Use NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.04 Restricted Use NICE TA367: Vortioxetine for treating major depressive episodes
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Bedfordshire and Luton Joint Formulary